$19.53 B
Share price
Change (1 day)
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

BeiGene (BGNE) - Total liabilities

Total liabilities on the balance sheet as of June 2023 : $1.93 B

According to BeiGene 's latest financial reports the company's total liabilities are $1.93 B. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

BeiGene - Total liabilities on balance sheet (from 2014 to 2023)

Total liabilities by year

Year Total liabilities Change
2022-12-31$1.99 B-16.94%
2021-12-31$2.40 B38.78%
2020-12-31$1.73 B173.14%
2019-12-31$0.63 B27.8%
2018-12-31$0.49 B36.93%
2017-12-31$0.36 B-10.74%
2016-12-31$0.40 B247.55%
2015-12-31$0.11 B319.22%
2014-12-31$27.85 M-44.87%
2013-12-31$50.52 M

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
$0.62 B-67.69%๐Ÿ‡บ๐Ÿ‡ธ USA
$11.57 M-99.40%๐Ÿ‡บ๐Ÿ‡ธ USA